Coverage
-
June 14, 2013
Impax Laboratories Inc. has agreed to license Shire PLC's patents for the attention deficit hyperactivity disorder drug Intuniv, resolving Shire's infringement litigation over Impax's bid to launch a generic version of the drug, according to settlement papers filed Thursday in California federal court.
1 other articles on this case.
View all »